Can an arthritis drug tame deadly dengue inflammation?

NCT ID NCT05611710

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether anakinra, an anti-inflammatory drug, can help people with severe dengue who have dangerously high inflammation. About 160 adults and children will receive either anakinra or a placebo for four days. The goal is to see if anakinra reduces organ failure and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Anakinra (an anti-inflammatory drug given intravenously)

What this could lead to

If it works, this could offer a way to prevent organ failure in severe dengue patients with dangerous inflammation.

What could go wrong

This is a mid-stage trial with only 160 participants, so results may not apply to all dengue patients. Anakinra may not improve outcomes and could have side effects like increased infection risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DENGUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome dengue disease Dengue hemorrhagic fever dengue shock syndrome hemophagocytic syndrome macrophage activation syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital for Tropical Diseases

    Ho Chi Minh City, Vietnam